



6 January 2022

Release of Shares from Voluntary Escrow

Creso Pharma Limited (ASX: “CPH”, the “Company” or “Creso”) advises in accordance with Listing Rule 3.10A, that a total of 46,802,872 fully paid ordinary shares (“Shares”) will be released from voluntary escrow on Friday, 14 January 2022.

The securities to be released from voluntary escrow were issued as part of the consideration payable to the vendors of Halucenex Life Sciences Inc. upon the completion of the Company’s acquisition of Halucenex Life Sciences Inc. in July 2021.

The Company applied for, and was subsequently granted, quotation of 29,251,795 Shares on 14 July 2021 and 17,551,077 Shares on 9 December 2021. Following the release of Shares from voluntary escrow on 14 January 2022, the holding lock applicable to 29,251,795 Shares will be lifted prior to the commencement of trade on 14 January 2022.

As noted in the ASX release dated 9 December 2021, the residual 17,551,077 Shares will remain subject to a holding lock until the Company releases a cleansing prospectus in respect of these Shares for the purpose of removing on-sale restrictions in early 2022.

As of the date of this release, the Company has no further securities subject to escrow restrictions.

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Board of Directors of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

Creso Pharma Limited
E: info@cresopharma.com
P: +61 (0) 497 571 532

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which



enhance the bioavailability and absorption of cannabinoids. To learn more please visit:
www.cresopharma.com

Creso Pharma offices:

Australia

Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Switzerland

Allmendstrasse 11, 6310 Steinhausen, Schweiz

Canada

59 Payzant Driver, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0